Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.

Bone marrow transplantation·2026
Same author

Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy.

American journal of hematology·2026
Same author

Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Case Report: Sustained immune and pulmonary recovery three years after hematopoietic stem cell transplantation for ITCH E3 ubiquitin ligase deficiency.

Frontiers in immunology·2026
Same author

Electrophysiology of Neuromuscular Disorders in Critical Illness.

Muscle & nerve·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

Paraproteinemic neuropathy.

Sasa A Zivković1, David Lacomis, Suzanne Lentzsch

  • 1VA Pittsburgh Healthcare System, MSSL-Neurology, Pittsburgh, PA, USA. zivkovics@upmc.edu

Leukemia & Lymphoma
|July 29, 2009
PubMed
Summary
This summary is machine-generated.

Monoclonal gammopathy of undetermined significance can cause paraproteinemic neuropathy (PPN). Monitoring for malignant conversion and understanding treatment risks are crucial for managing PPN.

More Related Videos

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Related Experiment Videos

Last Updated: Jun 21, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Area of Science:

  • Neurology
  • Hematology
  • Immunology

Background:

  • Monoclonal proteins (paraproteins) are found in about 1% of the general population and often linked to peripheral neuropathy.
  • Paraproteinemic neuropathy (PPN) is commonly associated with monoclonal gammopathy of undetermined significance (MGUS) but can also occur with multiple myeloma, amyloidosis, and other hematologic conditions.
  • Malignant transformation of benign monoclonal gammopathy requires monitoring, with neuropathy progression and rising protein titers as risk factors.

Purpose of the Study:

  • To review the association between monoclonal proteins and peripheral neuropathy.
  • To discuss the diagnostic considerations and therapeutic strategies for paraproteinemic neuropathy.
  • To highlight the importance of monitoring for malignant conversion in patients with monoclonal gammopathy.

Main Methods:

  • Literature review of studies on paraproteinemic neuropathy.
  • Analysis of the association between monoclonal proteins and peripheral nerve autoantibodies (e.g., anti-MAG, anti-GM1).
  • Evaluation of treatment outcomes for different types of PPN.

Main Results:

  • PPN is frequently linked to autoantibodies targeting peripheral nerve antigens.
  • Treatment primarily focuses on the underlying hematologic disorder, with careful risk-benefit assessment.
  • Rituximab shows promise for IgM-PPN; IVIG is effective for multifocal motor neuropathy; plasmapheresis is more effective for IgG/IgA PPN.

Conclusions:

  • The management of PPN involves treating the underlying hematologic condition, considering specific therapies like Rituximab, IVIG, or plasmapheresis based on paraprotein type.
  • Close monitoring for malignant conversion is essential, especially with worsening neuropathy or increasing monoclonal protein levels.
  • Further research is needed to determine if neuropathy presence alone warrants aggressive treatment of quiescent hematologic malignancies.